` NTHI (NeOnc Technologies Holdings Inc) vs S&P 500 Comparison - Alpha Spread

N
NTHI
vs
S&P 500

Over the past 12 months, NTHI has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +14% growth.

Stocks Performance
NTHI vs S&P 500

Loading
NTHI
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NTHI vs S&P 500

Performance Gap Between NTHI and GSPC
HIDDEN
Show

Performance By Year
NTHI vs S&P 500

Loading
NTHI
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
NeOnc Technologies Holdings Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

NeOnc Technologies Holdings Inc
Glance View

Market Cap
136.5m USD
Industry
Pharmaceuticals

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

NTHI Intrinsic Value
HIDDEN
Show
Back to Top